Related Experiment Video
Updated: Mar 10, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Watchman Device: Left Atrial Appendage Closure For Stroke Prophylaxis In Atrial Fibrillation
Dr Manoj N Obeyesekere Mbbs Mrcp Fracp Fhrs1
1The Northern Hospital, 185, Cooper Street, Epping, Victoria AUSTRALIA.
Insights
Many atrial fibrillation patients stop blood thinners or face bleeding risks. The WATCHMAN device offers a potentially safer alternative for stroke prevention in nonvalvular AF.
Area of Science:
- Cardiology
- Medical Devices
- Thrombosis Management
Background:
- Many atrial fibrillation (AF) patients discontinue oral anticoagulation (OAC) or are not prescribed it, despite stroke risk.
- High-risk AF patients often face both embolic and hemorrhagic complications, complicating OAC therapy.
Approach:
- This review examines medium-term efficacy and safety data for the WATCHMAN device.
- It discusses left atrial appendage (LAA) closure techniques, focusing on the WATCHMAN device.
- Crucial technical points for WATCHMAN implantation are also addressed.
Key Points:
- The WATCHMAN device is the most studied LAA closure device, with unique randomized and medium-term follow-up data.
- It presents a viable alternative to chronic warfarin therapy for nonvalvular AF patients.
- Understanding implantation techniques is crucial for successful LAA closure.
Conclusions:
- The WATCHMAN device demonstrates potential as an effective and safe alternative to OAC in select AF patients.
- Further research and technical refinement can optimize LAA closure therapy.
- This approach may reduce bleeding risks associated with long-term anticoagulation.
Abstract:
A concerning proportion of patients with atrial fibrillation (AF) with indications for oral anticoagulation (OAC) discontinue OAC or are never prescribed OAC therapy and many AF patients with the highest risk for embolic events off OAC also have the greatest risk for hemorrhagic complications on OACs. Medium-term efficacy and safety data provide evidence that the WATCHMAN device, the most studied device and the only one with randomized and medium-term follow-up data, may be a viable alternative to chronic warfarin therapy in nonvalvular AF patients. In addition to presenting key data pertaining to LAA closure techniques including the WATCHMAN device, this review will discuss crucial WATCHMAN implantation technical points.
